Other current and non-current assets

12 Months Ended

Dec. 31, 2020

8.	Other current and non-current assets

Other current assets


	As of
	December 31, 2020		December 31, 2019
	(Euros in thousands)
Grant receivable		875		998
Prepaid expenses		2,389		1,236
Positive market value forward contract		914		—
Value added tax receivable		798		768
Capitalized transaction costs		—		48
Other assets		787		617

Other current assets		5,763		3,667

The Group recognizes receivables for government grants when it is reasonably assured that the grant will be received, and all contractual conditions have been complied with. As of December 31, 2020, and 2019, no receivables were considered impaired.

Prepaid expenses include prepaid insurance expenses of €1.0 million and €0.1 million as of December 31, 2020 and 2019, respectively. The Group paid €0.5 million and €0.6 million of incremental cost for the successful arrangement of the Celgene Switzerland LLC (“BMS”) and Genmab A/S (“Genmab”) collaboration agreements as of December 31, 2020 and 2019, respectively. Additionally, prepaid expenses include expenses for licenses and software of €0.6 million and €0.2 million as of December 31, 2020 and 2019, respectively. The remaining amount is related to prepaid maintenance expenses.

Other assets include receivables from capital gains tax of €0.4 million and €0.3 million as of December 31, 2020 and 2019, respectively. The remaining amount is related to prepaid deposit expenses.

Other

non-current

assets


	As of
	December 31, 2020		December 31, 2019
	(Euros in thousands)
Prepaid expenses		724		937
Other non-current assets		—		325

Total non-current assets		724		1,262

Prepaid expenses consist of €0.7 million and €0.9 million of incremental cost paid for the successful arrangement of the BMS and Genmab collaboration agreements as of December 31, 2020 and 2019, respectively.